Whatcom Health Information Network is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dr. Katie Rodan and Dr. Kathy Fields met at Stanford University during their dermatology residency bonding over their personal struggles with acne and an understanding of how skin issues impact self-esteem and self-confidence. They combined their personal connection and professional expertise into a shared mission: to provide everyone with life-changing skincareTM that deliver real results! Today, Rodan + Fields has grown from its humble beginnings in Dr. Katie Rodan`s kitchen to the #1 skincare brand in the U.S. in 2016.* We combine our innovative products with a high-tech, high-touch approach, and as a result, more than a million customers have experienced the benefits of Rodan + Fields. We are transforming skincare, and we welcome your big ideas to fuel our ambitious growth plans! If you are looking for a life-changing career opportunity, we`ve got your prescription. At Rodan + Fields, you will be challenged to make an impact, inspired to do more, and rewarded for your contributions.
NuvoAir is a virtual first specialty care provider that empowers and engages people living with complex heart and lung conditions like COPD, Congestive Heart Failure (CHF), and Asthma around the world.
Your partner in Care is a Wakefield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.